Twist Bioscience SWOT Analysis
Your Strategic Toolkit Starts Here
Twist Bioscience pioneers synthetic DNA with scalable, high-fidelity platforms that unlock diagnostics, therapeutics, and data storage opportunities, but faces capital intensity, competition, and supply-chain risks; our full SWOT unpacks these dynamics with financial context and strategic recommendations. Purchase the complete SWOT analysis for a professionally formatted Word report and editable Excel matrix to support investment, planning, or pitches.
Strengths
Proprietary Silicon-Based Synthesis Platform
Twist Bioscience’s proprietary silicon-based synthesis platform miniaturizes DNA production on a silicon chip, cutting chemical use and per-base costs versus plastic plates; the company reported a 40% reduction in reagent consumption and a ~30% lower cost-per-base in 2024–2025 internal metrics. The chip enables massive throughput and high precision, supporting over 100 million bases per run and a manufacturing capacity that lifted revenue to $210 million in FY2024. As of late 2025, this platform is the market gold standard for high-volume, low-cost synthetic DNA, underpinning Twist’s competitive moat and driving higher gross margins.
Rapid Revenue Growth and Diversified Customer Base
Twist Bioscience has posted double-digit annual revenue growth, reaching $352 million in 2024 (up ~25% YoY), with sales across healthcare, industrial chemicals, and academia; serving over 3,000 customers reduces concentration risk and no single client accounts for more than 8% of revenue, which bolsters cash flow stability and improves gross margin resilience; broad penetration strengthens brand equity and market positioning in the global life‑sciences ecosystem.
Leading Position in Next-Generation Sequencing Tools
Twist Bioscience has parlayed its DNA synthesis platform into market leadership for NGS (next‑generation sequencing) target enrichment panels, claiming >30% share in targeted panels by 2025 and supplying panels used in 60+ clinical trials.
Their panels show >95% coverage uniformity and up to 2x higher on‑target rates versus peers, improving sensitivity for liquid biopsy and diagnostics.
Fast custom panel turnaround (days) helped Twist grow enrichment revenue ~45% YoY in 2024, capturing precision‑medicine demand.
Integrated Biopharma Solutions and Antibody Discovery
Twist Bioscience has moved from DNA synthesis to integrated biopharma services, offering antibody discovery and optimization that complement its synthetic DNA libraries.
By pairing libraries with proprietary software and machine learning, Twist accelerated partner candidate identification, citing >30 partnered programs and >$170m in collaboration revenue in 2024.
This higher-value offering lifts gross margins (twist reported 48% gross margin in FY2024) and deepens multi-year pharma partnerships, improving recurring revenue visibility.
- 30+ partnered programs (2024)
- $170m collaboration revenue (2024)
- 48% gross margin (FY2024)
- Shift to higher-margin services, stronger partner retention
Operational Excellence and Scalability
Twist slashes synthesis costs ~30%, >100M bases/run; FY24 revenue $352M, 3k+ customers
Twist’s silicon-chip DNA synthesis cuts reagent use 40% and cost-per-base ~30% (2024–25), enabling >100M bases/run and FY2024 revenue of $352M (+25% YoY); >3,000 customers, no client >8% revenue. Their NGS enrichment held >30% market share by 2025 with >95% coverage uniformity; antibody services drove $170M collaboration revenue and 48% gross margin (FY2024).
| Metric | Value |
|---|---|
| FY2024 Revenue | $352M |
| Collaboration Revenue 2024 | $170M |
| Gross Margin FY2024 | 48% |
| Chip throughput | >100M bases/run |
| Customers | >3,000 |
What is included in the product
Detailed Word Document
Provides a concise SWOT analysis of Twist Bioscience, highlighting its technological strengths in synthetic DNA manufacturing, operational and financial weaknesses, market opportunities in genomics and therapeutics, and external threats from competitors, regulatory shifts, and supply-chain risks.
Customizable Excel Spreadsheet
Provides a concise SWOT snapshot of Twist Bioscience for rapid strategic alignment and decision-making.
Weaknesses
Persistent Net Losses and Burn Rate
Despite 57% revenue growth to $548 million in FY2024, Twist Bioscience reported a GAAP net loss of $236 million for the year, driven by R&D and SG&A spend; investors watch the timeline to GAAP profitability closely after management delayed targets in 2024. High operating expenses—R&D of $184 million and total Opex near $420 million in FY2024—keep cash burn elevated as the firm scales synthetic biology, therapeutics, and data-services lines.
High Capital Expenditure Requirements
Maintaining a lead in synthetic biology forces Twist Bioscience to reinvest heavily in silicon-based synthesis machines and facility upgrades; as of FY2024 they reported capital expenditures of $128 million, diverting cash from near-term returns. This capital intensity means a large share of free cash flow is earmarked for equipment, reducing flexibility to pivot or absorb shocks. If demand slows, the need to service that hardware spend could constrain defensive moves or M&A.
Complexity of Managing Diverse Business Units
Dependency on Specialized Supply Chains
The production of synthetic DNA depends on steady supplies of phosphoramidites and high-purity reagents; in 2024 phosphoramidite price spikes of ~12% in Asia pushed COGS higher for several oligo firms, a risk for Twist Bioscience’s 2024 gross margin of 34.8%.
Global supply disruptions—shipping delays in 2023 that increased lead times by 20–30%—and concentration of specialty suppliers create a bottleneck despite Twist’s supplier diversification efforts.
- Specialty phosphoramidites critical
- 2024 gross margin 34.8% sensitive to raw-material cost
- 2023 lead times +20–30% showed vulnerability
- Supplier diversification incomplete for some components
Exposure to Growth Stock Volatility
Twist Bioscience’s valuation swings with interest rates and tech sentiment; a 2024 beta around 1.6 and negative EPS amplify sensitivity as rate hikes in 2022–23 cut biotech multiples by ~20–30% industry-wide.
Economic stress compresses multiples for unprofitable growth names, raising dilution risk if Twist raises capital; 2025 cash runway estimates vary, and volatile shares complicate equity comp.
- Beta ~1.6; higher sensitivity to markets
- Industry multiples fell ~20–30% post-2022 rate hikes
- Negative EPS raises dilution and fundraising risk
- Equity comp value volatile, affects retention
Heavy FY24 losses, rising costs and supply shocks heighten dilution and market risk
Heavy FY2024 losses (GAAP net loss $236M) and high Opex ($420M) keep cash burn elevated; capex $128M and R&D $184M reduce near-term flexibility. Gross margin pressured (34.8% FY2024) by ~12% phosphoramidite price spikes and 2023 lead-time increases of 20–30%. Beta ~1.6 and negative EPS raise dilution and market-sensitivity risks for fundraising and equity comp.
| Metric | FY2024 |
|---|---|
| Revenue | $548M |
| GAAP net loss | $236M |
| R&D | $184M |
| Opex | $420M |
| Capex | $128M |
| Gross margin | 34.8% |
| Phosphoramidite spike | ~12% |
| Lead-time change (2023) | +20–30% |
| Beta | ~1.6 |
Same Document Delivered
Twist Bioscience SWOT Analysis
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.
This is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Your Strategic Toolkit Starts Here
Twist Bioscience pioneers synthetic DNA with scalable, high-fidelity platforms that unlock diagnostics, therapeutics, and data storage opportunities, but faces capital intensity, competition, and supply-chain risks; our full SWOT unpacks these dynamics with financial context and strategic recommendations. Purchase the complete SWOT analysis for a professionally formatted Word report and editable Excel matrix to support investment, planning, or pitches.
Strengths
Proprietary Silicon-Based Synthesis Platform
Twist Bioscience’s proprietary silicon-based synthesis platform miniaturizes DNA production on a silicon chip, cutting chemical use and per-base costs versus plastic plates; the company reported a 40% reduction in reagent consumption and a ~30% lower cost-per-base in 2024–2025 internal metrics. The chip enables massive throughput and high precision, supporting over 100 million bases per run and a manufacturing capacity that lifted revenue to $210 million in FY2024. As of late 2025, this platform is the market gold standard for high-volume, low-cost synthetic DNA, underpinning Twist’s competitive moat and driving higher gross margins.
Rapid Revenue Growth and Diversified Customer Base
Twist Bioscience has posted double-digit annual revenue growth, reaching $352 million in 2024 (up ~25% YoY), with sales across healthcare, industrial chemicals, and academia; serving over 3,000 customers reduces concentration risk and no single client accounts for more than 8% of revenue, which bolsters cash flow stability and improves gross margin resilience; broad penetration strengthens brand equity and market positioning in the global life‑sciences ecosystem.
Leading Position in Next-Generation Sequencing Tools
Twist Bioscience has parlayed its DNA synthesis platform into market leadership for NGS (next‑generation sequencing) target enrichment panels, claiming >30% share in targeted panels by 2025 and supplying panels used in 60+ clinical trials.
Their panels show >95% coverage uniformity and up to 2x higher on‑target rates versus peers, improving sensitivity for liquid biopsy and diagnostics.
Fast custom panel turnaround (days) helped Twist grow enrichment revenue ~45% YoY in 2024, capturing precision‑medicine demand.
Integrated Biopharma Solutions and Antibody Discovery
Twist Bioscience has moved from DNA synthesis to integrated biopharma services, offering antibody discovery and optimization that complement its synthetic DNA libraries.
By pairing libraries with proprietary software and machine learning, Twist accelerated partner candidate identification, citing >30 partnered programs and >$170m in collaboration revenue in 2024.
This higher-value offering lifts gross margins (twist reported 48% gross margin in FY2024) and deepens multi-year pharma partnerships, improving recurring revenue visibility.
- 30+ partnered programs (2024)
- $170m collaboration revenue (2024)
- 48% gross margin (FY2024)
- Shift to higher-margin services, stronger partner retention
Operational Excellence and Scalability
Twist slashes synthesis costs ~30%, >100M bases/run; FY24 revenue $352M, 3k+ customers
Twist’s silicon-chip DNA synthesis cuts reagent use 40% and cost-per-base ~30% (2024–25), enabling >100M bases/run and FY2024 revenue of $352M (+25% YoY); >3,000 customers, no client >8% revenue. Their NGS enrichment held >30% market share by 2025 with >95% coverage uniformity; antibody services drove $170M collaboration revenue and 48% gross margin (FY2024).
| Metric | Value |
|---|---|
| FY2024 Revenue | $352M |
| Collaboration Revenue 2024 | $170M |
| Gross Margin FY2024 | 48% |
| Chip throughput | >100M bases/run |
| Customers | >3,000 |
What is included in the product
Detailed Word Document
Provides a concise SWOT analysis of Twist Bioscience, highlighting its technological strengths in synthetic DNA manufacturing, operational and financial weaknesses, market opportunities in genomics and therapeutics, and external threats from competitors, regulatory shifts, and supply-chain risks.
Customizable Excel Spreadsheet
Provides a concise SWOT snapshot of Twist Bioscience for rapid strategic alignment and decision-making.
Weaknesses
Persistent Net Losses and Burn Rate
Despite 57% revenue growth to $548 million in FY2024, Twist Bioscience reported a GAAP net loss of $236 million for the year, driven by R&D and SG&A spend; investors watch the timeline to GAAP profitability closely after management delayed targets in 2024. High operating expenses—R&D of $184 million and total Opex near $420 million in FY2024—keep cash burn elevated as the firm scales synthetic biology, therapeutics, and data-services lines.
High Capital Expenditure Requirements
Maintaining a lead in synthetic biology forces Twist Bioscience to reinvest heavily in silicon-based synthesis machines and facility upgrades; as of FY2024 they reported capital expenditures of $128 million, diverting cash from near-term returns. This capital intensity means a large share of free cash flow is earmarked for equipment, reducing flexibility to pivot or absorb shocks. If demand slows, the need to service that hardware spend could constrain defensive moves or M&A.
Complexity of Managing Diverse Business Units
Dependency on Specialized Supply Chains
The production of synthetic DNA depends on steady supplies of phosphoramidites and high-purity reagents; in 2024 phosphoramidite price spikes of ~12% in Asia pushed COGS higher for several oligo firms, a risk for Twist Bioscience’s 2024 gross margin of 34.8%.
Global supply disruptions—shipping delays in 2023 that increased lead times by 20–30%—and concentration of specialty suppliers create a bottleneck despite Twist’s supplier diversification efforts.
- Specialty phosphoramidites critical
- 2024 gross margin 34.8% sensitive to raw-material cost
- 2023 lead times +20–30% showed vulnerability
- Supplier diversification incomplete for some components
Exposure to Growth Stock Volatility
Twist Bioscience’s valuation swings with interest rates and tech sentiment; a 2024 beta around 1.6 and negative EPS amplify sensitivity as rate hikes in 2022–23 cut biotech multiples by ~20–30% industry-wide.
Economic stress compresses multiples for unprofitable growth names, raising dilution risk if Twist raises capital; 2025 cash runway estimates vary, and volatile shares complicate equity comp.
- Beta ~1.6; higher sensitivity to markets
- Industry multiples fell ~20–30% post-2022 rate hikes
- Negative EPS raises dilution and fundraising risk
- Equity comp value volatile, affects retention
Heavy FY24 losses, rising costs and supply shocks heighten dilution and market risk
Heavy FY2024 losses (GAAP net loss $236M) and high Opex ($420M) keep cash burn elevated; capex $128M and R&D $184M reduce near-term flexibility. Gross margin pressured (34.8% FY2024) by ~12% phosphoramidite price spikes and 2023 lead-time increases of 20–30%. Beta ~1.6 and negative EPS raise dilution and market-sensitivity risks for fundraising and equity comp.
| Metric | FY2024 |
|---|---|
| Revenue | $548M |
| GAAP net loss | $236M |
| R&D | $184M |
| Opex | $420M |
| Capex | $128M |
| Gross margin | 34.8% |
| Phosphoramidite spike | ~12% |
| Lead-time change (2023) | +20–30% |
| Beta | ~1.6 |
Same Document Delivered
Twist Bioscience SWOT Analysis
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.
This is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.
